Abionyx Pharma: insider trades · France · AMF

About Abionyx Pharma

ABIONYX PHARMA is a French biotechnology company listed on Euronext Paris under ticker ABNX and ISIN FR0012616852, and it is eligible for the PEA PME scheme. The group positions itself as a next-generation biopharma company focused on developing innovative biologics built on its proprietary apoA-I recombinant technology platform. ApoA-I is a key protein involved in lipid transport and inflammatory regulation, and ABIONYX uses this scientific foundation to target severe diseases with high unmet medical needs, especially in sepsis and critical care, while also pursuing rare diseases and selected renal and ophthalmic indications. The company’s roots are linked to Cerenis Therapeutics, with a strategic repositioning toward apoA-I-based therapeutics and HDL-derived vectors. ABIONYX’s headquarters are in Balma, near Toulouse, France, and the group also maintains a U.S. presence, including operations in Lakeland and Westlake Village. As of 31 December 2024, the company owned 100% of Cerenis Therapeutics Inc. in the United States and 100% of APOGEYE Pharma, which itself owns IRIS Pharma, a France-based ophthalmology-focused CRO. This structure gives ABIONYX both a clinical development platform and a revenue-generating service subsidiary. ABIONYX’s core business is centered on research, clinical development, and industrial preparation of apoA-I-based bioproducts. Its main focus areas include sepsis, severe inflammatory diseases, rare disorders, and targeted drug delivery through new HDL vectors. The company also emphasizes a meaningful intellectual property portfolio, with patent families spanning the United States, Europe, Japan, China, and other jurisdictions, supporting the long-term defensibility of its technology platform. From a market standpoint, ABIONYX PHARMA remains a specialty small-cap biotech at an earlier stage of development, with its therapeutic business still largely pre-commercial. In 2025, consolidated revenue came solely from IRIS Pharma, while the biotechnology activities had not yet generated revenue. Nevertheless, the group has reported a number of recent scientific, regulatory, and financing milestones, including a successful pre-IND meeting with the FDA for CER-001 in sepsis, a positive EMA opinion in LCAT deficiency, Bpifrance support for ophthalmology development, and financing measures extending cash visibility. Taken together, these milestones underline a company in transition, combining science, IP, partnerships, and clinical execution to build long-term value in major unmet-need areas.